Evidence map›Paper›PMID 29286914›Full record

ArticleCancer biomarkers : section A of Disease markers2018

TP53 p.R72P genotype is a marker of poor prognosis in lung cancer.

Mirko Peter Neumann, María Victoria González, Ana S Pitiot, Íñigo Santamaría, Cristina Martínez, Adonina Tardón, Aurora Astudillo, Milagros Balbín

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Mirko Peter NeumannDepartment of Pathology, Hospital Universitario Central de Asturias and Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain.
María Victoria GonzálezDepartment of Surgery, University of Oviedo and IUOPA, Oviedo, Spain.
Ana S PitiotLaboratorio de Oncología Molecular, IUOPA and Laboratorio de Medicina, HUCA, Oviedo, Spain.
Íñigo SantamaríaLaboratorio de Oncología Molecular, IUOPA and Laboratorio de Medicina, HUCA, Oviedo, Spain.
Cristina MartínezServicio de Neumología, Area de Gestión Clínica de Pulmón, Instituto Nacional de Silicosis, HUCA, Oviedo, Spain.
Adonina TardónIUOPA, University of Oviedo and CIBERESP (Ciber de Epidemiologia y salud Pública), Oviedo, Spain.
Aurora AstudilloDepartment of Surgery, University of Oviedo and IUOPA, Oviedo, Spain.
Milagros BalbínLaboratorio de Oncología Molecular, IUOPA and Laboratorio de Medicina, HUCA, Oviedo, Spain.
Instituto de Investigación Sanitaria del Principado de Asturias · ESCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ESInstituto Nacional de Silicosis · ESUniversidad de Oviedo · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLung cancer is a leading cause of death worldwide, with poor survival rates despite diagnostic and therapeutic advances. Markers are needed in order to improve clinical patient management and survival. TP53 is frequently involved in lung cancer development with polymorphic sites potentially having a role in it. This study aims to determine the value of codon 72 missense polymorphic variant genotyping, TP53 R72P, as a prognostic factor in NSCLC patients.

methodsOne hundred and fifteen NSCLC samples from patients exposed to tobacco smoke and silica dust from Asturias (Northern Spain) were genotyped by direct sequencing.

resultsSeventy-five percent tumour samples alleles coded for Arg. The R72P genotype was an independent predictor of lymph node status (HR = 3.6). The heterozygous genotype was associated to a reduced 5-year survival rate (28% vs 51% for homozygotes). Importantly, this result was specifically observed in these subsets of patients: those over 67 years, patients with silicosis, current smokers, patients with squamous cell carcinomas and, notably, with tumour free lymph nodes.

conclusionOur results indicate a remarkable application of R72P genotyping in the clinical setting: refine patient subclassification to identify those with an adverse clinical course despite tumour free lymph node status.

Indexed as

AgedAged, 80 and overBiomarkers, TumorCarcinoma, Non-Small-Cell LungDisease-Free SurvivalFemaleGenotypeHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedPolymorphism, Single NucleotidePrognosisProportional Hazards ModelsTumor Suppressor Protein p53Biomarkers, TumorTP53 protein, humanTumor Suppressor Protein p53NSCLCpolymorphismprognosisR72PTP53

Identifiers

PMID29286914
PMCPMC13078336
OpenAlexW2777195241

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.